Bayesian Optimal Phase II design with optimised stopping boundaries and response-adaptive randomisation
By: Connor Fitchett , Ayon Mukherjee , Sofía S. Villar and more
Potential Business Impact:
Improves cancer drug tests for better results.
The Bayesian Optimal Phase II (BOP2) framework is a flexible trial design that can naturally facilitate complex adaptations due to its Bayesian setting. BOP2 uses equal randomisation and equally placed interim analyses in its design, but it is unclear whether these give the best operating characteristics. By incorporating Bayesian Response-Adaptive Randomisation (BRAR) and optimal interim analysis placement, we show that allocation to the best treatment and expected sample size can be improved with minimal impact on power. We discuss recommendations on implementing these adaptations, using simulation-based evidence, to give practical advice to practitioners. Reproducible code for the simulations is freely provided.
Similar Papers
A Bayesian Optimal Phase II Design for Randomized Immunotherapy Trials with Delayed Treatment Effects
Methodology
Helps cancer drugs work sooner by testing them better.
A Comparative Evaluation of Bayesian Model-Assisted Two-Stage Designs for Phase I/II Clinical Trials
Methodology
Finds best medicine dose for trials.
The Bayesian optimal two-stage design for clinical phase II trials based on Bayes factors
Methodology
Tests new medicines faster and with fewer people.